Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21111019 | 1.00 | MMP2 (0.36) | MMP2ANPEPPOLBL3MBTL1SLC6A12 | |
| SCHEMBL376608 | 1.00 | MMP2 (0.36) | MMP2ANPEPPOLBL3MBTL1SLC6A12 | |
| Hydrochloric Acid SCHEMBL21682304 | 0.98 | MMP2 (0.35) | MMP2ANPEPPOLBL3MBTL1SLC6A12 | |
| Hydrochloric Acid SCHEMBL15265472 | 0.98 | MMP2 (0.35) | MMP2ANPEPPOLBL3MBTL1SLC6A12 | |
| SCHEMBL13288149 | 0.84 | MMP2 (0.36) | MMP2ANPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL21110975 | 0.82 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL22557213 | 0.82 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL4368534 | 0.82 | MMP2 (0.50) | MMP2ANPEPPOLBL3MBTL1 | |
| SCHEMBL30476580 | 0.82 | MMP2 (0.50) | MMP2ANPEPPOLBL3MBTL1 | |
| SCHEMBL22556879 | 0.82 | MMP2 (0.35) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393923-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | Yiyou Biotech (Shanghai) Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-04-11 | — | — | US | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023115327-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | CYP1B1, CYP2D6, CYP1A1 | MMP2 4419/4885ANPEP 3612/4885POLB 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.